Showing 1–6 of 9 results

990.00 Excl. VAT

RNA science is now translated into new therapies… Six RNA-based products are now approved More than one hundred candidates have reached the clinical stage…  “BRIEFING ON RNA TRIALS” provides you an accurate overview to explore the latest trials in this dynamic and rapidly evolving field FOUR REASONS TO BUY: Wishing to identify hot research topics in [...]

1,090.00 Excl. VAT

BioPharmAnalyses and Octopusyx BioConsulting are happy to announce the release of the second issue of their “BRIEFING ON CART-T CELLS TRIALS”   At least 5 reasons to buy “BRIEFING ON CART-T CELLS TRIALS” More than 140 new clinical trials registered between 01/01/2018 and 12/01/2019 For each clinical trial mentioned, a novel format enriched by relevant contextualisation [...]

3,490.00 Excl. VAT

BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled « Landscape in Gene Therapy Companies » In this 800-pages report, a must-have read one, you will find -More than 230 closely scrutinized companies -More than 600 products identified including more than 200 products at the clinical stage -More than 300 VC or investors mentioned -Mor than 200 pathologies referred -A detailed Overview of Companies involved in AAV-based gene therapy, LV-based Gene Therapy, Gene Therapy, CDMO (Contracts, Manufacturing Organisation) and a Miscellaneous section including Hubs and Non Viral Gene Transfer) CAR-T strategies will be dealt separately in the updated edition of our Briefing on CAR-T clinical trials. The 2019 edition will be published next November For further information, alb@biopharmanalyses.fr or olivier@octopusyx.fr  

Sale!
1,490.00 890.00 Excl. VAT

Our Briefing on RNA Trials provides you with an accurate overview to explore the latest trials in the RNA therapeutic area 86 pages detailing 101 clinical trials conducted in 44 countries -42 companies and academic institutions developing 78 RNA products (antisense oligonucleotides, RNAi/siRNA, microRNAs, mRNAs) -55 targets and 57 diseases in a wide range of [...]